{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:47:19Z","timestamp":1795060039929,"version":"4.10.2"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["DK139454-01"],"award-info":[{"award-number":["DK139454-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11886-025-02274-z","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:20:32Z","timestamp":1755012032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Optimizing Care for Cardiovascular-Kidney-Metabolic Syndrome: Leveraging Implementation Science in the Path Toward Pharmacoequity"],"prefix":"10.1007","volume":"27","author":[{"given":"Regina M.","family":"Longley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Katzenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinushika","family":"Mohottige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"issue":"8","key":"2274_CR1","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","volume":"147","author":"CW Tsao","year":"2023","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke Statistics\u20142023 update: A report from the American heart association. Circulation. 2023;147(8):e93\u2013621.","journal-title":"Circulation"},{"issue":"1","key":"2274_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5334\/gh.1288","volume":"19","author":"M Di Cesare","year":"2024","unstructured":"Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, et al. The heart of the world. Glob Heart. 2024;19(1):11.","journal-title":"Glob Heart"},{"issue":"20","key":"2274_CR3","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic health: A presidential advisory from the American heart association. Circulation. 2023;148(20):1606\u201335.","journal-title":"Circulation"},{"issue":"21","key":"2274_CR4","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1001\/jama.2024.6892","volume":"331","author":"R Aggarwal","year":"2024","unstructured":"Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of Cardiovascular-Kidney-Metabolic syndrome stages in US adults, 2011\u20132020. JAMA. 2024;331(21):1858\u201360.","journal-title":"JAMA"},{"issue":"11","key":"2274_CR5","doi-asserted-by":"publisher","first-page":"e2445309","DOI":"10.1001\/jamanetworkopen.2024.45309","volume":"7","author":"R Zhu","year":"2024","unstructured":"Zhu R, Wang R, He J, Wang L, Chen H, Niu X, et al. Prevalence of Cardiovascular-Kidney-Metabolic syndrome stages by social determinants of health. JAMA Netw Open. 2024;7(11):e2445309\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2274_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1215\/03616878-10041135","volume":"47","author":"R Chalasani","year":"2022","unstructured":"Chalasani R, Krishnamurthy S, Suda KJ, Newman TV, Delaney SW, Essien UR. Pursuing pharmacoequity: determinants, drivers, and pathways to progress. J Health Polit Policy Law. 2022;47(6):709\u201329.","journal-title":"J Health Polit Policy Law"},{"issue":"20","key":"2274_CR7","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A synopsis of the evidence for the science and clinical management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: A scientific statement from the American heart association. Circulation. 2023;148(20):1636\u201364.","journal-title":"Circulation"},{"issue":"16","key":"2274_CR8","doi-asserted-by":"publisher","first-page":"e036518","DOI":"10.1161\/JAHA.124.036518","volume":"13","author":"AK April-Sanders","year":"2024","unstructured":"April-Sanders AK. Integrating social determinants of health in the management of Cardiovascular\u2010Kidney\u2010Metabolic syndrome. J Am Heart Association. 2024;13(16):e036518.","journal-title":"J Am Heart Association"},{"issue":"4","key":"2274_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223\u201337.","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"2274_CR10","doi-asserted-by":"publisher","first-page":"e008888","DOI":"10.1161\/JAHA.118.008888","volume":"7","author":"KS Dorans","year":"2018","unstructured":"Dorans KS, Mills KT, Liu Y, He J. Trends in prevalence and control of hypertension according to the 2017 American college of cardiology\/american heart association (ACC\/AHA) guideline. J Am Heart Association. 2018;7(11):e008888.","journal-title":"J Am Heart Association"},{"issue":"1","key":"2274_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11886-022-01826-x","volume":"25","author":"AA Abrahamowicz","year":"2023","unstructured":"Abrahamowicz AA, Ebinger J, Whelton SP, Commodore-Mensah Y, Yang E. Racial and ethnic disparities in hypertension: barriers and opportunities to improve blood pressure control. Curr Cardiol Rep. 2023;25(1):17\u201327.","journal-title":"Curr Cardiol Rep"},{"issue":"10","key":"2274_CR12","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/jch.13089","volume":"19","author":"KC Ferdinand","year":"2017","unstructured":"Ferdinand KC, Yadav K, Nasser SA, Clayton-Jeter HD, Lewin J, Cryer DR, et al. Disparities in hypertension and cardiovascular disease in blacks: the critical role of medication adherence. J Clin Hypertens (Greenwich). 2017;19(10):1015\u201324.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"24","key":"2274_CR13","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1016\/j.jacc.2021.06.017","volume":"78","author":"MO Ogunniyi","year":"2021","unstructured":"Ogunniyi MO, Commodore-Mensah Y, Ferdinand KC, Race. Ethnicity, hypertension, and heart disease: JACC focus seminar 1\/9. J Am Coll Cardiol. 2021;78(24):2460\u201370.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2274_CR14","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1161\/HYPERTENSIONAHA.121.17570","volume":"78","author":"R Aggarwal","year":"2021","unstructured":"Aggarwal R, Chiu N, Wadhera RK, Moran AE, Raber I, Shen C, et al. Racial\/Ethnic disparities in hypertension prevalence, awareness, treatment, and control in the united states, 2013 to 2018. Hypertension. 2021;78(6):1719\u201326.","journal-title":"Hypertension"},{"issue":"6","key":"2274_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/ajh\/hpac011","volume":"35","author":"DK Hayes","year":"2022","unstructured":"Hayes DK, Jackson SL, Li Y, Wozniak G, Tsipas S, Hong Y, et al. Blood pressure control among Non-Hispanic black adults is lower than Non-Hispanic white adults despite similar treatment with antihypertensive medication: NHANES 2013\u20132018. Am J Hypertens. 2022;35(6):514\u201325.","journal-title":"Am J Hypertens"},{"issue":"16","key":"2274_CR16","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1007\/s11606-022-07776-y","volume":"37","author":"UR Essien","year":"2022","unstructured":"Essien UR, Corbie G. Getting under the skin: Race-Based guidelines and the pursuit of pharmacoequity. J Gen Intern Med. 2022;37(16):4035\u20136.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"2274_CR17","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/ajh\/hpae093","volume":"37","author":"JM Flack","year":"2024","unstructured":"Flack JM, Bitner S, Buhnerkempe M. Evolving the role of black race in hypertension therapeutics. Am J Hypertens. 2024;37(10):739\u201344.","journal-title":"Am J Hypertens"},{"issue":"1","key":"2274_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3122\/jabfm.2022.01.210276","volume":"35","author":"HK Holt","year":"2022","unstructured":"Holt HK, Gildengorin G, Karliner L, Fontil V, Pramanik R, Potter MB. Differences in hypertension medication prescribing for black Americans and their association with hypertension outcomes. J Am Board Family Med. 2022;35(1):26\u201334.","journal-title":"J Am Board Family Med"},{"key":"2274_CR19","doi-asserted-by":"publisher","first-page":"116938","DOI":"10.1016\/j.socscimed.2024.116938","volume":"351","author":"CJ Rabay","year":"2024","unstructured":"Rabay CJ, Lopez C, Streuli S, Mayes EC, Rajagopalan RM, Non AL. Clinicians\u2019 perspectives on race-specific guidelines for hypertensive treatment. Soc Sci Med. 2024;351:116938.","journal-title":"Soc Sci Med"},{"issue":"1","key":"2274_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1089\/heq.2023.0064","volume":"7","author":"LC Savage","year":"2023","unstructured":"Savage LC, Panofsky A. The Self-Fulfilling process of clinical race correction: the case of eighth joint National committee recommendations. Health Equity. 2023;7(1):793\u2013802.","journal-title":"Health Equity"},{"issue":"2","key":"2274_CR21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/HYPERTENSIONAHA.121.17102","volume":"79","author":"BM Egan","year":"2022","unstructured":"Egan BM, Yang J, Rakotz MK, Sutherland SE, Jamerson KA, Wright JT, et al. Self-Reported antihypertensive medication class and Temporal relationship to treatment guidelines. Hypertension. 2022;79(2):338\u201348.","journal-title":"Hypertension"},{"issue":"16","key":"2274_CR22","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1007\/s11606-022-07612-3","volume":"37","author":"TS Anderson","year":"2022","unstructured":"Anderson TS, Ayanian JZ, Zaslavsky AM, Souza J, Landon BE. National trends in antihypertensive treatment among older adults by race and presence of comorbidity, 2008 to 2017. J Gen Intern Med. 2022;37(16):4223\u201332.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"2274_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1161\/HYPERTENSIONAHA.120.16281","volume":"77","author":"CD Chu","year":"2021","unstructured":"Chu CD, Powe NR, McCulloch CE, Banerjee T, Crews DC, Saran R, et al. Angiotensin-Converting enzyme inhibitor or angiotensin receptor blocker use among hypertensive US adults with albuminuria. Hypertension. 2021;77(1):94\u2013102.","journal-title":"Hypertension"},{"key":"2274_CR24","doi-asserted-by":"publisher","first-page":"117954681983941","DOI":"10.1177\/1179546819839418","volume":"13","author":"A Gu","year":"2019","unstructured":"Gu A, Farzadeh SN, Chang YJ, Kwong A, Lam S. Patterns of antihypertensive drug utilization among US adults with diabetes and comorbid hypertension: the National health and nutrition examination survey 1999\u20132014. Clin Med Insights: Cardiol. 2019;13:1179546819839418.","journal-title":"Clin Med Insights: Cardiol"},{"issue":"24","key":"2274_CR25","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1001\/jama.2024.6774","volume":"331","author":"L Shen","year":"2024","unstructured":"Shen L, Lee MMY, Jhund PS, Granger CB, Anand IS, Maggioni AP, et al. Revisiting race and the benefit of RAS Blockade in heart failure: A Meta-Analysis of randomized clinical trials. JAMA. 2024;331(24):2094\u2013104.","journal-title":"JAMA"},{"issue":"2","key":"2274_CR26","doi-asserted-by":"publisher","first-page":"151520","DOI":"10.1016\/j.semnephrol.2024.151520","volume":"44","author":"CP Limonte","year":"2024","unstructured":"Limonte CP, Lamprea-Montealegre JA, Tuttle KR. Challenges and strategies in implementing novel kidney protective and cardioprotective therapies in patients with diabetes and kidney disease. Semin Nephrol. 2024;44(2):151520.","journal-title":"Semin Nephrol"},{"issue":"6","key":"2274_CR27","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1002\/ehf2.13169","volume":"7","author":"J Butler","year":"2020","unstructured":"Butler J, Usman MS, Khan MS, Greene SJ, Friede T, Vaduganathan M, et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Fail. 2020;7(6):3298\u2013309.","journal-title":"ESC Heart Fail"},{"issue":"2","key":"2274_CR28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A Meta-analysis. JAMA Cardiol. 2021;6(2):148\u201358.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"2274_CR29","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"25","key":"2274_CR30","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","volume":"81","author":"S Usman Muhammad","year":"2023","unstructured":"Usman Muhammad S, Siddiqi Tariq J, Anker Stefan D, Bakris George L, Bhatt Deepak L, Filippatos G, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023;81(25):2377\u201387.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"2274_CR31","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","volume":"149","author":"SM Patel","year":"2024","unstructured":"Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, et al. Sodium-Glucose Cotransporter-2 inhibitors and major adverse cardiovascular outcomes: A SMART-C collaborative Meta-Analysis. Circulation. 2024;149(23):1789\u2013801.","journal-title":"Circulation"},{"issue":"6","key":"2274_CR32","doi-asserted-by":"publisher","first-page":"108204","DOI":"10.1016\/j.jdiacomp.2022.108204","volume":"36","author":"CP Limonte","year":"2022","unstructured":"Limonte CP, Hall YN, Trikudanathan S, Tuttle KR, Hirsch IB, de Boer IH, et al. Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes. J Diabetes Complicat. 2022;36(6):108204.","journal-title":"J Diabetes Complicat"},{"key":"2274_CR33","doi-asserted-by":"crossref","unstructured":"Nicholas SB, Daratha KB, Alicic RZ, Jones CR, Kornowske LM, Neumiller JJ et al. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019\u20132020. Diabetes, Obesity and Metabolism. 2023;25(10):2970-9.","DOI":"10.1111\/dom.15194"},{"issue":"13","key":"2274_CR34","doi-asserted-by":"publisher","first-page":"e021084","DOI":"10.1161\/JAHA.121.021084","volume":"10","author":"AA Nargesi","year":"2021","unstructured":"Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary National patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus. J Am Heart Association. 2021;10(13):e021084.","journal-title":"J Am Heart Association"},{"issue":"4","key":"2274_CR35","doi-asserted-by":"publisher","first-page":"e216139","DOI":"10.1001\/jamanetworkopen.2021.6139","volume":"4","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Eneanya ND, Essien U, Julien H, Nathan AS, et al. Association of race\/ethnicity, gender, and socioeconomic status with Sodium-Glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Netw Open. 2021;4(4):e216139.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2274_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"12","key":"2274_CR37","doi-asserted-by":"publisher","first-page":"e214182","DOI":"10.1001\/jamahealthforum.2021.4182","volume":"2","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Essien UR, Eneanya ND, Julien HM, Luo J, et al. Racial, ethnic, and socioeconomic inequities in Glucagon-Like Peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum. 2021;2(12):e214182.","journal-title":"JAMA Health Forum"},{"issue":"8","key":"2274_CR38","doi-asserted-by":"publisher","first-page":"100510","DOI":"10.1016\/j.xkme.2022.100510","volume":"4","author":"JZ Zhao","year":"2022","unstructured":"Zhao JZ, Weinhandl ED, Carlson AM, St Peter WL. Hypoglycemia risk with SGLT2 inhibitors or Glucagon-Like peptide 1 receptor agonists versus sulfonylureas among medicare insured adults with CKD in the united States. Kidney Med. 2022;4(8):100510.","journal-title":"Kidney Med"},{"issue":"15","key":"2274_CR39","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1177\/2047487317729252","volume":"24","author":"SV Arnold","year":"2020","unstructured":"Arnold SV, Inzucchi SE, Tang F, McGuire DK, Mehta SN, Maddox TM, et al. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR\u00ae research to practice project. Eur J Prev Cardiol. 2020;24(15):1637\u201345.","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"2274_CR40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","volume":"135","author":"LS Phillips","year":"2001","unstructured":"Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825\u201334.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2274_CR41","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/ndt\/gfac283","volume":"38","author":"R Nee","year":"2023","unstructured":"Nee R, Yuan CM, Narva AS, Yan G, Norris KC. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol Dial Transpl. 2023;38(3):532\u201341.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"2274_CR42","doi-asserted-by":"publisher","first-page":"151519","DOI":"10.1016\/j.semnephrol.2024.151519","volume":"44","author":"D Mohottige","year":"2024","unstructured":"Mohottige D. Paving a path to equity in cardiorenal care. Semin Nephrol. 2024;44(2):151519.","journal-title":"Semin Nephrol"},{"key":"2274_CR43","doi-asserted-by":"crossref","unstructured":"Patel PM, Essien UR, Happe L. Pharmacoequity measurement framework: A tool to reduce health disparities. J Managed Care Specialty Pharm. 2025;0(0):1\u201311.","DOI":"10.18553\/jmcp.2025.24298"},{"issue":"11","key":"2274_CR44","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1161\/HYPERTENSIONAHA.124.20533","volume":"81","author":"ST Hardy","year":"2024","unstructured":"Hardy ST, Fontil V, Dillon GH, Shimbo D. Achieving equity in hypertension: A review of current efforts by the American heart association. Hypertension. 2024;81(11):2218\u201327.","journal-title":"Hypertension"},{"issue":"1","key":"2274_CR45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1377\/hlthaff.28.1.75","volume":"28","author":"K Coleman","year":"2009","unstructured":"Coleman K, Austin BT, Brach C, Wagner EH. Evidence on the chronic care model in the new millennium. Health Aff. 2009;28(1):75\u201385.","journal-title":"Health Aff"},{"key":"2274_CR46","doi-asserted-by":"publisher","unstructured":"Si D, Bailie R, Cunningham J, Robinson G, Dowden M, Stewart A, Connors C, Weeramanthri T. Describing and analysing primary health care system support for chronic illness care in Indigenous communities in Australia\u2019s Northern Territory \u2013 use of the Chronic Care Model. BMC Health Serv Res. 2008;8:112. https:\/\/doi.org\/10.1186\/1472-6963-8-112","DOI":"10.1186\/1472-6963-8-112"},{"key":"2274_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jcte.2016.12.001","volume":"7","author":"M McGill","year":"2017","unstructured":"McGill M, Blonde L, Chan JCN, Khunti K, Lavalle FJ, Bailey CJ. The interdisciplinary team in type 2 diabetes management: challenges and best practice solutions from real-world scenarios. J Clin Translational Endocrinol. 2017;7:21\u20137.","journal-title":"J Clin Translational Endocrinol"},{"issue":"3","key":"2274_CR48","first-page":"315","volume":"11","author":"X Wu","year":"2024","unstructured":"Wu X, Li Z, Tian Q, Ji S, Zhang C. Effectiveness of nurse-led heart failure clinic: A systematic review. Int J Nurs Sci. 2024;11(3):315\u201329.","journal-title":"Int J Nurs Sci"},{"issue":"4","key":"2274_CR49","doi-asserted-by":"publisher","first-page":"299","DOI":"10.4103\/jpbs.JPBS_138_19","volume":"11","author":"MZ Iqbal","year":"2019","unstructured":"Iqbal MZ, Khan AH, Iqbal MS, Syed Sulaiman SA. A review of Pharmacist-led interventions on diabetes outcomes: an observational analysis to explore diabetes care opportunities for pharmacists. J Pharm Bioallied Sci. 2019;11(4):299\u2013309.","journal-title":"J Pharm Bioallied Sci"},{"issue":"3","key":"2274_CR50","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/cd22-0094","volume":"41","author":"NR Giruzzi","year":"2023","unstructured":"Giruzzi NR, Yepez C, McKeirnan K. Impact of a Pharmacist-Led diabetes care service for Hispanic patients at a free medical clinic. Clin Diabetes. 2023;41(3):420\u20134.","journal-title":"Clin Diabetes"},{"issue":"9","key":"2274_CR51","doi-asserted-by":"publisher","first-page":"e2335409","DOI":"10.1001\/jamanetworkopen.2023.35409","volume":"6","author":"KDC Narain","year":"2023","unstructured":"Narain KDC, Moreno G, Bell DS, Chen L, Tseng C-H, Follett RW, et al. Pharmacist-Led diabetes control intervention and health outcomes in Hispanic patients with diabetes. JAMA Netw Open. 2023;6(9):e2335409\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2274_CR52","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41371-020-0331-7","volume":"34","author":"TD Wagner","year":"2020","unstructured":"Wagner TD, Jones MC, Salgado TM, Dixon DL. Pharmacist\u2019s role in hypertension management: a review of key randomized controlled trials. J Hum Hypertens. 2020;34(7):487\u201394.","journal-title":"J Hum Hypertens"},{"issue":"7","key":"2274_CR53","doi-asserted-by":"publisher","first-page":"e004386","DOI":"10.1161\/CIRCOUTCOMES.117.004386","volume":"11","author":"V Fontil","year":"2018","unstructured":"Fontil V, Gupta R, Moise N, Chen E, Guzman D, McCulloch CE, et al. Adapting and evaluating a health system intervention from Kaiser permanente to improve hypertension management and control in a large network of Safety-Net clinics. Circ Cardiovasc Qual Outcomes. 2018;11(7):e004386.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2274_CR54","doi-asserted-by":"publisher","first-page":"263348952110494","DOI":"10.1177\/26334895211049482","volume":"2","author":"RC Shelton","year":"2021","unstructured":"Shelton RC, Adsul P, Oh A, Moise N, Griffith DM. Application of an antiracism lens in the field of implementation science (IS): recommendations for reframing implementation research with a focus on justice and Racial equity. Implement Res Pract. 2021;2:26334895211049482.","journal-title":"Implement Res Pract"},{"key":"2274_CR55","doi-asserted-by":"publisher","unstructured":"Shelton RC, Chambers DA, Glasgow RE. An extension of RE-AIM to enhance sustainability: addressing dynamic context and promoting health equity over time. Front Public Health. 2020;8:134. https:\/\/doi.org\/10.3389\/fpubh.2020.00134","DOI":"10.3389\/fpubh.2020.00134"},{"issue":"1","key":"2274_CR56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.pcad.2019.12.005","volume":"63","author":"DP Ferdinand","year":"2020","unstructured":"Ferdinand DP, Nedunchezhian S, Ferdinand KC. Hypertension in African americans: advances in community outreach and public health approaches. Prog Cardiovasc Dis. 2020;63(1):40\u20135.","journal-title":"Prog Cardiovasc Dis"},{"issue":"14","key":"2274_CR57","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1056\/NEJMoa1717250","volume":"378","author":"RG Victor","year":"2018","unstructured":"Victor RG, Lynch K, Li N, Blyler C, Muhammad E, Handler J, et al. A Cluster-Randomized trial of Blood-Pressure reduction in black barbershops. N Engl J Med. 2018;378(14):1291\u2013301.","journal-title":"N Engl J Med"},{"issue":"20","key":"2274_CR58","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1161\/CIRCULATIONAHA.109.873232","volume":"122","author":"E Lonn","year":"2010","unstructured":"Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases. Circulation. 2010;122(20):2078\u201388.","journal-title":"Circulation"},{"issue":"22","key":"2274_CR59","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1001\/jama.2020.21395","volume":"324","author":"A Agarwal","year":"2020","unstructured":"Agarwal A, Yancy CW, Huffman MD. Improving care for heart failure with reduced ejection Fraction-A potential Polypill-Based strategy. JAMA. 2020;324(22):2259\u201360.","journal-title":"JAMA"},{"key":"2274_CR60","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijcard.2022.04.085","volume":"360","author":"MMG Mohamed","year":"2022","unstructured":"Mohamed MMG, Osman M, Kheiri B, Saleem M, Lacasse A, Alkhouli M. Polypill for cardiovascular disease prevention: systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2022;360:91\u20138.","journal-title":"Int J Cardiol"},{"issue":"16","key":"2274_CR61","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/eurjpc\/zwad245","volume":"30","author":"A Rivera","year":"2023","unstructured":"Rivera A, Campos B, Ceolin S, Godoi A, Castanha E, Campello Jorge CA, et al. Polypill-based strategy vs. usual care for secondary prevention of cardiovascular disease: a meta-analysis of randomized controlled trials. Eur J Prev Cardiol. 2023;30(16):1828\u201337.","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"2274_CR62","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1815359","volume":"381","author":"D Mu\u00f1oz","year":"2019","unstructured":"Mu\u00f1oz D, Uzoije P, Reynolds C, Miller R, Walkley D, Pappalardo S, et al. Polypill for cardiovascular disease prevention in an underserved population. N Engl J Med. 2019;381(12):1114\u201323.","journal-title":"N Engl J Med"},{"key":"2274_CR63","doi-asserted-by":"crossref","unstructured":"Kohli-Lynch CN, Moran AE, Kazi DS, Bibbins-Domingo K, Jordan N, French D et al. Cost-Effectiveness of a polypill for cardiovascular disease prevention in an underserved population. JAMA Cardiol. 2025;10(3):224\u2013233.","DOI":"10.1001\/jamacardio.2024.4812"},{"key":"2274_CR64","doi-asserted-by":"crossref","unstructured":"Chen JC, DeJong C, Agarwal M, Hairston AM, Durstenfeld MS, McKay V et al. Stakeholder Perspectives on a Heart Failure With Reduced Ejection Fraction Polypill: A Multi-Center Mixed Methods Study. Circulation: Cardiovascular Quality and Outcomes. 2024;17(11):e011121.","DOI":"10.1161\/CIRCOUTCOMES.124.011121"},{"issue":"10073","key":"2274_CR65","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S0140-6736(17)30558-5","volume":"389","author":"R Webster","year":"2017","unstructured":"Webster R, Castellano JM, Onuma OK. Putting polypills into practice: challenges and lessons learned. Lancet. 2017;389(10073):1066\u201374.","journal-title":"Lancet"},{"issue":"5","key":"2274_CR66","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1001\/jamainternmed.2023.8315","volume":"184","author":"L Samal","year":"2024","unstructured":"Samal L, Kilgallon JL, Lipsitz S, Baer HJ, McCoy A, Gannon M, et al. Clinical decision support for hypertension management in chronic kidney disease: A randomized clinical trial. JAMA Intern Med. 2024;184(5):484\u201392.","journal-title":"JAMA Intern Med"},{"issue":"7","key":"2274_CR67","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jamainternmed.2024.0708","volume":"184","author":"M Jhamb","year":"2024","unstructured":"Jhamb M, Weltman MR, Devaraj SM, Lavenburg L-MU, Han Z, Alghwiri AA, et al. Electronic health record population health management for chronic kidney disease care: A cluster randomized clinical trial. JAMA Intern Med. 2024;184(7):737\u201347.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"2274_CR68","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2105\/AJPH.89.9.1322","volume":"89","author":"RE Glasgow","year":"1999","unstructured":"Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322\u20137.","journal-title":"Am J Public Health"},{"key":"2274_CR69","doi-asserted-by":"publisher","unstructured":"Feldstein AC, Glasgow RE. A practical, robust implementation and sustainability model (PRISM) for integrating research findings into practice. Joint Commission J Qual Patient Saf. 2008;34(4):228\u2013243. https:\/\/doi.org\/10.1016\/S1553-7250(08)34030-6","DOI":"10.1016\/S1553-7250(08)34030-6"},{"key":"2274_CR70","doi-asserted-by":"crossref","unstructured":"Fraser SDS, Taal MW. Multimorbidity in people with chronic kidney disease: implications for outcomes and treatment. Curr Opin Nephrol Hypertens. 2016;25(6):465\u2013472.","DOI":"10.1097\/MNH.0000000000000270"},{"issue":"9","key":"2274_CR71","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2215\/CJN.0000000000000498","volume":"19","author":"KJ Mayne","year":"2024","unstructured":"Mayne KJ, Sardell RJ, Staplin N, Judge PK, Zhu D, Sammons E, et al. Frailty, multimorbidity, and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial. Clin J Am Soc Nephrol. 2024;19(9):1119\u201329.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2274_CR72","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s13340-021-00495-5","volume":"12","author":"H \u0130nci","year":"2021","unstructured":"\u0130nci H. Evaluation of multiple drug use in patients with type 2 diabetes mellitus. Diabetol Int. 2021;12(4):399\u2013404.","journal-title":"Diabetol Int"},{"issue":"6","key":"2274_CR73","doi-asserted-by":"publisher","first-page":"841","DOI":"10.34067\/KID.0000000000000447","volume":"5","author":"IJ Oosting","year":"2024","unstructured":"Oosting IJ, Colombijn JMT, Kaasenbrood L, Liabeuf S, Laville SM, Hooft L, et al. Polypharmacy in patients with CKD: A systematic review and Meta-Analysis. Kidney360. 2024;5(6):841\u201350.","journal-title":"Kidney360"},{"issue":"4","key":"2274_CR74","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s43587-021-00045-3","volume":"1","author":"RS Mehta","year":"2021","unstructured":"Mehta RS, Kochar BD, Kennelty K, Ernst ME, Chan AT. Emerging approaches to polypharmacy among older adults. Nat Aging. 2021;1(4):347\u201356.","journal-title":"Nat Aging"},{"issue":"9","key":"2274_CR75","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.34067\/KID.0001942021","volume":"2","author":"D Mohottige","year":"2021","unstructured":"Mohottige D, Manley HJ, Hall RK. Less is more: deprescribing medications in older adults with kidney disease: A review. Kidney360. 2021;2(9):1510\u201322.","journal-title":"Kidney360"},{"key":"2274_CR76","doi-asserted-by":"publisher","first-page":"100477","DOI":"10.1016\/j.ajpc.2023.100477","volume":"13","author":"A Khedagi","year":"2023","unstructured":"Khedagi A, Hoke C, Kelsey M, Coviello A, Jones WS, Jackson LR 2, et al. Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists. Am J Prev Cardiol. 2023;13:100477.","journal-title":"Am J Prev Cardiol"},{"issue":"4","key":"2274_CR77","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.xkme.2021.03.014","volume":"3","author":"CD Chu","year":"2021","unstructured":"Chu CD, Chen MH, McCulloch CE, Powe NR, Estrella MM, Shlipak MG, et al. Patient awareness of CKD: A systematic review and Meta-analysis of Patient-Oriented questions and study setting. Kidney Med. 2021;3(4):576\u2013e851.","journal-title":"Kidney Med"},{"issue":"3","key":"2274_CR78","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.ackd.2010.03.002","volume":"17","author":"LC Plantinga","year":"2010","unstructured":"Plantinga LC, Tuot DS, Powe NR. Awareness of chronic kidney disease among patients and providers. Adv Chronic Kidney Dis. 2010;17(3):225\u201336.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"2274_CR79","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12882-024-03466-5","volume":"25","author":"DR Farrell","year":"2024","unstructured":"Farrell DR, Vassalotti JA. Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what? BMC Nephrol. 2024;25(1):34.","journal-title":"BMC Nephrol"},{"issue":"1","key":"2274_CR80","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12933-020-01154-w","volume":"19","author":"G Schernthaner","year":"2020","unstructured":"Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19(1):185.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"2274_CR81","doi-asserted-by":"publisher","first-page":"e214205","DOI":"10.1001\/jamahealthforum.2021.4205","volume":"2","author":"SL Tummalapalli","year":"2021","unstructured":"Tummalapalli SL, Montealegre JL, Warnock N, Green M, Ibrahim SA, Estrella MM, Coverage. Formulary restrictions, and affordability of Sodium-Glucose cotransporter 2 inhibitors by US insurance plan types. JAMA Health Forum. 2021;2(12):e214205\u2013e.","journal-title":"JAMA Health Forum"},{"issue":"4","key":"2274_CR82","doi-asserted-by":"publisher","first-page":"415","DOI":"10.18553\/jmcp.2022.21385","volume":"28","author":"P McEwan","year":"2022","unstructured":"McEwan P, Morgan AR, Boyce R, Green N, Song B, Huang J, et al. Cardiorenal disease in the united states: future health care burden and potential impact of novel therapies. J Managed Care Specialty Pharm. 2022;28(4):415\u201324.","journal-title":"J Managed Care Specialty Pharm"},{"key":"2274_CR83","doi-asserted-by":"crossref","unstructured":"Ying X, Kahn P, Mathis WS. Pharmacy deserts: More than where pharmacies are. J Am Pharm Assoc (2003). 2022;62(6):1875-9.","DOI":"10.1016\/j.japh.2022.06.016"},{"issue":"8","key":"2274_CR84","doi-asserted-by":"publisher","first-page":"e2429755","DOI":"10.1001\/jamanetworkopen.2024.29755","volume":"7","author":"G Catalano","year":"2024","unstructured":"Catalano G, Khan MMM, Chatzipanagiotou OP, Pawlik TM. Pharmacy accessibility and social vulnerability. JAMA Netw Open. 2024;7(8):e2429755.","journal-title":"JAMA Netw Open"},{"issue":"16","key":"2274_CR85","doi-asserted-by":"publisher","first-page":"e034996","DOI":"10.1161\/JAHA.124.034996","volume":"13","author":"J Li","year":"2024","unstructured":"Li J, Lei L, Wang W, Ding W, Yu Y, Pu B, et al. Social risk profile and Cardiovascular-Kidney\u2010Metabolic syndrome in US adults. J Am Heart Association. 2024;13(16):e034996.","journal-title":"J Am Heart Association"},{"issue":"19","key":"2274_CR86","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New Creatinine- and Cystatin C\u2013Based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737\u201349.","journal-title":"N Engl J Med"},{"issue":"9","key":"2274_CR87","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s11606-019-05108-1","volume":"34","author":"A Barghi","year":"2019","unstructured":"Barghi A, Torres H, Kressin NR, McCormick D. Coverage and access for Americans with cardiovascular disease or risk factors after the ACA: a Quasi-experimental study. J Gen Intern Med. 2019;34(9):1797\u2013805.","journal-title":"J Gen Intern Med"},{"key":"2274_CR88","unstructured":"Artiga S, Young K, Garfield R, Majerol M. Racial and ethnic disparities in access to and utilization of care among insured adults. Henry J. Kaiser Family Foundation; 2015."},{"issue":"7","key":"2274_CR89","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1056\/NEJMp1306636","volume":"369","author":"BD Sommers","year":"2013","unstructured":"Sommers BD. Stuck between health and immigration Reform \u2014 Care for undocumented immigrants. N Engl J Med. 2013;369(7):593\u20135.","journal-title":"N Engl J Med"},{"issue":"4","key":"2274_CR90","doi-asserted-by":"publisher","first-page":"464","DOI":"10.2105\/AJPH.2017.304277","volume":"108","author":"CG Victora","year":"2018","unstructured":"Victora CG, Joseph G, Silva ICM, Maia FS, Vaughan JP, Barros FC, et al. The inverse equity hypothesis: analyses of institutional deliveries in 286 National surveys. Am J Public Health. 2018;108(4):464\u201371.","journal-title":"Am J Public Health"},{"key":"2274_CR91","doi-asserted-by":"crossref","unstructured":"Bozkurt B, Ahmad T, Alexander K, Baker WL, Bosak K, Breathett K et al. HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the heart failure society of America. Journal of Cardiac Failure. 2025.","DOI":"10.1016\/j.cardfail.2024.07.001"},{"issue":"5","key":"2274_CR92","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/ckj\/sfac258","volume":"16","author":"R de la Espriella","year":"2023","unstructured":"de la Espriella R, Marcos MC, Ronco C, Banerjee D, Gonz\u00e1lez M, G\u00f3rriz JL, et al. Practical approaches to Building up a cardiorenal clinic. Clin Kidney J. 2023;16(5):780\u201392.","journal-title":"Clin Kidney J"},{"issue":"11","key":"2274_CR93","doi-asserted-by":"publisher","first-page":"e007264","DOI":"10.1161\/CIRCOUTCOMES.120.007264","volume":"13","author":"J Rangaswami","year":"2020","unstructured":"Rangaswami J, Tuttle K, Vaduganathan M. Cardio-Renal-Metabolic care models: toward achieving effective interdisciplinary care. Circ Cardiovasc Qual Outcomes. 2020;13(11):e007264.","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02274-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02274-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02274-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:04:40Z","timestamp":1772096680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02274-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2274"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02274-z","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"28 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"No animal or human subjects by the authors were used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"122"}}